IL172759A0 - Pyrrole-2,5-dithione derivatives as liver x receptor modulators - Google Patents
Pyrrole-2,5-dithione derivatives as liver x receptor modulatorsInfo
- Publication number
- IL172759A0 IL172759A0 IL172759A IL17275905A IL172759A0 IL 172759 A0 IL172759 A0 IL 172759A0 IL 172759 A IL172759 A IL 172759A IL 17275905 A IL17275905 A IL 17275905A IL 172759 A0 IL172759 A0 IL 172759A0
- Authority
- IL
- Israel
- Prior art keywords
- pyrrole
- liver
- receptor modulators
- dithione
- derivatives
- Prior art date
Links
- 102000004311 liver X receptors Human genes 0.000 title 1
- 108090000865 liver X receptors Proteins 0.000 title 1
- DVUZQONFTJKFPV-UHFFFAOYSA-N pyrrole-2,5-dithione Chemical class S=C1NC(=S)C=C1 DVUZQONFTJKFPV-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0316237.7A GB0316237D0 (en) | 2003-07-11 | 2003-07-11 | Therapeutic agents |
| PCT/SE2004/001115 WO2005005416A1 (en) | 2003-07-11 | 2004-07-08 | Pyrrole-2, 5-dithione derivatives as liver x receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL172759A0 true IL172759A0 (en) | 2006-04-10 |
Family
ID=27741986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL172759A IL172759A0 (en) | 2003-07-11 | 2005-12-22 | Pyrrole-2,5-dithione derivatives as liver x receptor modulators |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20060189663A1 (https=) |
| EP (1) | EP1646625B1 (https=) |
| JP (1) | JP2007521313A (https=) |
| KR (1) | KR20060034284A (https=) |
| CN (1) | CN100478340C (https=) |
| AR (1) | AR045720A1 (https=) |
| AT (1) | ATE399776T1 (https=) |
| AU (1) | AU2004256000B2 (https=) |
| BR (1) | BRPI0412479A (https=) |
| CA (1) | CA2532068A1 (https=) |
| CO (1) | CO5640134A2 (https=) |
| DE (1) | DE602004014772D1 (https=) |
| ES (1) | ES2308205T3 (https=) |
| GB (1) | GB0316237D0 (https=) |
| IL (1) | IL172759A0 (https=) |
| IS (1) | IS8291A (https=) |
| MX (1) | MXPA06000447A (https=) |
| NO (1) | NO20060080L (https=) |
| RU (1) | RU2006102129A (https=) |
| SA (1) | SA04250203B1 (https=) |
| TW (1) | TW200507836A (https=) |
| UA (1) | UA82108C2 (https=) |
| UY (1) | UY28407A1 (https=) |
| WO (1) | WO2005005416A1 (https=) |
| ZA (1) | ZA200600229B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0500058D0 (sv) * | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 5 |
| SE0500055D0 (sv) | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 3 |
| JP2008526841A (ja) | 2005-01-10 | 2008-07-24 | アストラゼネカ アクチボラグ | 肝臓ｘ受容体調節因子としてのイソチアゾール−３（２ｈ）−オン１，１−ジオキシドのアニリン系誘導体 |
| US7989179B2 (en) * | 2005-06-28 | 2011-08-02 | Daiichi Sankyo Company, Limited | LXR ligand testing method |
| ES2528797T3 (es) | 2006-08-21 | 2015-02-12 | Genentech, Inc. | Compuestos de aza-benzotiofenilo y métodos de uso |
| WO2008046014A1 (en) | 2006-10-12 | 2008-04-17 | Remedy Pharmaceuticals, Inc. | Treatment of alzheimer's disease using compounds that reduce the activity of non-selective ca++- activated atp-sensitive cation channels regulated by sur1 receptors |
| US10004703B2 (en) | 2006-10-12 | 2018-06-26 | Biogen Chesapeake Llc | Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels |
| WO2008103818A1 (en) * | 2007-02-21 | 2008-08-28 | University Of Louisville Research Foundation | Therapeutic cotinine compositions |
| ES2638977T3 (es) | 2007-12-04 | 2017-10-24 | Biogen Chesapeake Llc | Formulaciones y procedimientos mejorados para liofilización y liofilizados obtenidos por los mismos |
| US20110034560A1 (en) | 2008-01-29 | 2011-02-10 | Sven Jacobson | Liquid formulations of compounds active at sulfonylurea receptors |
| ES2426096T3 (es) | 2008-07-01 | 2013-10-21 | Genentech, Inc. | Derivados de isoindolona como inhibidores de la quinasa MEK y métodos de utilización |
| US8841462B2 (en) | 2008-07-01 | 2014-09-23 | Robert A. Heald | Bicyclic heterocycles as MEK kinase inhibitors |
| WO2012033353A2 (ko) | 2010-09-07 | 2012-03-15 | 서울대학교 산학협력단 | 세스터터핀 화합물 및 이들 물질의 용도 |
| WO2015106164A1 (en) | 2014-01-10 | 2015-07-16 | Rgenix, Inc. | Lxr agonists and uses thereof |
| EP3402477A4 (en) | 2016-01-11 | 2019-08-21 | The Rockefeller University | METHOD FOR THE TREATMENT OF DISEASES RELATED TO MYELOID-DERIVED SUPPRESSOR CELLS |
| CA3078981A1 (en) | 2017-11-21 | 2019-05-31 | Rgenix, Inc. | Polymorphs and uses thereof |
| KR200492570Y1 (ko) | 2018-12-04 | 2020-11-05 | 박규환 | 조립식 계단장치를 위한 발판 |
| TWI888447B (zh) | 2019-12-13 | 2025-07-01 | 美商因思博納公司 | 金屬鹽及其用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6111699A (en) * | 1998-10-08 | 2000-05-01 | Smithkline Beecham Plc | Novel method and compounds |
| JP2004500332A (ja) * | 1999-07-08 | 2004-01-08 | テュラリク インコーポレイテッド | Ｈｄｌコレステロール値を上昇させる組成物および方法 |
-
2003
- 2003-07-11 GB GBGB0316237.7A patent/GB0316237D0/en not_active Ceased
-
2004
- 2004-06-29 TW TW093119119A patent/TW200507836A/zh unknown
- 2004-07-05 SA SA4250203A patent/SA04250203B1/ar unknown
- 2004-07-08 ES ES04749151T patent/ES2308205T3/es not_active Expired - Lifetime
- 2004-07-08 AU AU2004256000A patent/AU2004256000B2/en not_active Ceased
- 2004-07-08 MX MXPA06000447A patent/MXPA06000447A/es not_active Application Discontinuation
- 2004-07-08 RU RU2006102129/04A patent/RU2006102129A/ru not_active Application Discontinuation
- 2004-07-08 BR BRPI0412479-0A patent/BRPI0412479A/pt not_active IP Right Cessation
- 2004-07-08 AR ARP040102418A patent/AR045720A1/es not_active Application Discontinuation
- 2004-07-08 JP JP2006520139A patent/JP2007521313A/ja not_active Withdrawn
- 2004-07-08 DE DE602004014772T patent/DE602004014772D1/de not_active Expired - Fee Related
- 2004-07-08 US US10/563,676 patent/US20060189663A1/en not_active Abandoned
- 2004-07-08 AT AT04749151T patent/ATE399776T1/de not_active IP Right Cessation
- 2004-07-08 CA CA002532068A patent/CA2532068A1/en not_active Abandoned
- 2004-07-08 WO PCT/SE2004/001115 patent/WO2005005416A1/en not_active Ceased
- 2004-07-08 KR KR1020067000616A patent/KR20060034284A/ko not_active Withdrawn
- 2004-07-08 EP EP04749151A patent/EP1646625B1/en not_active Expired - Lifetime
- 2004-07-08 CN CNB2004800197194A patent/CN100478340C/zh not_active Expired - Fee Related
- 2004-07-09 UY UY28407A patent/UY28407A1/es unknown
- 2004-08-07 UA UAA200600270A patent/UA82108C2/uk unknown
-
2005
- 2005-12-22 IL IL172759A patent/IL172759A0/en unknown
-
2006
- 2006-01-05 NO NO20060080A patent/NO20060080L/no not_active Application Discontinuation
- 2006-01-10 ZA ZA200600229A patent/ZA200600229B/xx unknown
- 2006-01-20 CO CO06005238A patent/CO5640134A2/es not_active Application Discontinuation
- 2006-02-09 IS IS8291A patent/IS8291A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY28407A1 (es) | 2005-02-28 |
| SA04250203B1 (ar) | 2008-02-25 |
| WO2005005416A1 (en) | 2005-01-20 |
| ATE399776T1 (de) | 2008-07-15 |
| CN1820003A (zh) | 2006-08-16 |
| KR20060034284A (ko) | 2006-04-21 |
| HK1088318A1 (en) | 2006-11-03 |
| GB0316237D0 (en) | 2003-08-13 |
| CN100478340C (zh) | 2009-04-15 |
| EP1646625A1 (en) | 2006-04-19 |
| CA2532068A1 (en) | 2005-01-20 |
| AR045720A1 (es) | 2005-11-09 |
| MXPA06000447A (es) | 2006-04-07 |
| IS8291A (is) | 2006-02-09 |
| UA82108C2 (uk) | 2008-03-11 |
| US20060189663A1 (en) | 2006-08-24 |
| DE602004014772D1 (de) | 2008-08-14 |
| JP2007521313A (ja) | 2007-08-02 |
| ZA200600229B (en) | 2007-04-25 |
| TW200507836A (en) | 2005-03-01 |
| AU2004256000B2 (en) | 2007-07-26 |
| BRPI0412479A (pt) | 2006-09-19 |
| NO20060080L (no) | 2006-02-08 |
| ES2308205T3 (es) | 2008-12-01 |
| AU2004256000A1 (en) | 2005-01-20 |
| CO5640134A2 (es) | 2006-05-31 |
| RU2006102129A (ru) | 2006-08-27 |
| EP1646625B1 (en) | 2008-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL177218A0 (en) | 3-substituted 1,5-diphenylpyrazole derivatives useful as cb1 modulators | |
| IL178767A0 (en) | Indolyl derivatives as liver - x - receptor modulators | |
| EP1773768B8 (en) | Pyrrole derivatives as pharmaceutical agents | |
| GB0400440D0 (en) | Receptor modulators | |
| ZA200600229B (en) | Pyrrole-2,5-dithione derivatives as Liver X receptor modulators | |
| AU2003259482A1 (en) | N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators | |
| IL172760A0 (en) | Pyrrole-2,5-dithione derivatives as liver x receptor modulators | |
| IL182739A0 (en) | Acylatednonadepsipeptides used as lysobactin derivatives | |
| PL1638940T3 (pl) | Pochodne pirolidyniowe jako ligandy dla receptora muskarynowego M3 | |
| ZA200506744B (en) | PyrazoloÄ1,5-AÜpyrimidine derivatives | |
| ZA200609234B (en) | Substituted azeplne derivatives as serotonin receptor modulators | |
| AU2003301299A1 (en) | Benzyl substituted (piperidin-4-yl) aminobenzamido derivatives as delta-opiod receptor modulators | |
| AP2501A (en) | Substituted pyrrole derivatives | |
| SG121943A1 (en) | Compositions for multi-color, light activated imaging | |
| IL173337A0 (en) | Receptor | |
| HK1112905A (en) | 5-thioxo-1,5-dihydro-2h-pyrrol-2-one derivatives as liver x receptor modulators | |
| ZA200606563B (en) | 3-Substituted 1,5-diphenylpyrazole derivatives useful as CB1 Modulators | |
| HK1095140A (en) | Pyrrolidine derivatives as cb1-receptor antagonists | |
| HK1084298A (zh) | 受体 | |
| GB0321998D0 (en) | Receptor | |
| AU2003904848A0 (en) | Receptor specific ligands | |
| HK1097253A (en) | Substituted hydroxyacetophenon derivatives | |
| IL173334A0 (en) | Thiazole derivatives as cannabinoid receptor modulators | |
| HK1106509A (en) | Pyrrolidine derivatives as muscarinic receptor antagonists | |
| HK1094968A (en) | Bazedoxifene ascorbate as selective estrogen receptor modulator |